Attached files

file filename
EX-99.1 - STATEMENT - MANHATTAN SCIENTIFICS INCmhtx_ex991.htm


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities and Exchange Act of 1934

Date of Report (Date of earliest reported): May 22, 2014
 
MANHATTAN SCIENTIFICS, INC.
 (Exact name of registrant as specified in charter)

Delaware
 
000-28411
 
85-0460639
(State or Other Jurisdiction of
Incorporation or Organization)
 
(Commission
File Number)
 
(IRS Employer
 Identification No.)

The Chrysler Building
405 Lexington Avenue, 26th Floor
New York, New York, 10174
 (Address of Principal Executive Offices) (Zip Code)

Registrant’s Telephone Number, including area code: (212) 541-2405
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 


 
 

 
 
Item 7.01 Regulation FD Disclosure

On May 22, 2014, Manhattan Scientifics Inc. (the “Company”) released a statement regarding the expected shipment of its MRX IITM instrument to MD Anderson.  A statement regarding this shipment is attached hereto as Exhibit 99.1.
 
The information in this Item 7.01 of this Current Report is furnished pursuant to Item 7.01 and shall not be deemed "filed" for any purpose, including for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that section. The information in this Current Report on Form 8-K shall not be deemed incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934 regardless of any general incorporation language in such filing.

This Form 8-K contains forward-looking statements, which are subject to a number of risks, assumptions and uncertainties that could cause the Company's actual results to differ materially from those projected in such forward-looking statements. Management at the Company believes that purchase of its shares should be considered to be at the high end of the risk spectrum. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.

Item 9.01      Financial Statements and Exhibits

Exhibit Number
 
Description
     
99.1
 
Statement dated May 22, 2014
 
 
2

 

SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
  MANHATTAN SCIENTIFICS, INC.  
       
Date: May 22, 2014
By:
/s/ Emmanuel Tsoupanarias  
New York, New York Name: Emmanuel Tsoupanarias  
  Title: Chief Executive Officer  
       
 
 
 
 
 
 3